BRPI0510245A - estatinas para o tratamento de hipertensão ocular e glaucoma - Google Patents

estatinas para o tratamento de hipertensão ocular e glaucoma

Info

Publication number
BRPI0510245A
BRPI0510245A BRPI0510245-6A BRPI0510245A BRPI0510245A BR PI0510245 A BRPI0510245 A BR PI0510245A BR PI0510245 A BRPI0510245 A BR PI0510245A BR PI0510245 A BRPI0510245 A BR PI0510245A
Authority
BR
Brazil
Prior art keywords
statins
glaucoma
treatment
ocular hypertension
coa reductase
Prior art date
Application number
BRPI0510245-6A
Other languages
English (en)
Inventor
Mark R Hellberg
Debra L Fleenor
Allan R Shepard
Iok-Hou Pang
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of BRPI0510245A publication Critical patent/BRPI0510245A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pyrane Compounds (AREA)

Abstract

ESTATINAS PARA O TRATAMENTO DE HIPERTENSãO OCULAR E GLAUCOMA presente invenção refere-se ao uso de inibidores de HMG-CoA reductase (por exemplo, estatinas) para tratar glaucoma, controlar a pressão intra-ocular, preservar o tecido trabecular da esclera, proteger contra neuro-degeneração ocular e/ou proteger contra retinopatia glaucomatosa. Os inibidores de HMG-CoA reductase preferidos, que são estatinas possuindo um valor de RI de 0,2 a 0,7 (por exemplo, pravastatina) são administrados através de aplicação tópica ao(s) olho(s) afetado(s) do paciente.
BRPI0510245-6A 2004-04-26 2005-04-25 estatinas para o tratamento de hipertensão ocular e glaucoma BRPI0510245A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56546904P 2004-04-26 2004-04-26
PCT/US2005/014255 WO2005105069A1 (en) 2004-04-26 2005-04-25 Statins for the treatment of ocular hypertension and glaucoma

Publications (1)

Publication Number Publication Date
BRPI0510245A true BRPI0510245A (pt) 2007-10-23

Family

ID=34966865

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510245-6A BRPI0510245A (pt) 2004-04-26 2005-04-25 estatinas para o tratamento de hipertensão ocular e glaucoma

Country Status (20)

Country Link
US (2) US20050239871A1 (pt)
EP (1) EP1740164B1 (pt)
JP (1) JP2007534699A (pt)
KR (2) KR20110091600A (pt)
CN (1) CN1946384B (pt)
AT (1) ATE404189T1 (pt)
AU (1) AU2005237543B2 (pt)
BR (1) BRPI0510245A (pt)
CA (1) CA2560167A1 (pt)
CY (1) CY1108490T1 (pt)
DE (1) DE602005008935D1 (pt)
DK (1) DK1740164T3 (pt)
ES (1) ES2311986T3 (pt)
HK (1) HK1102913A1 (pt)
MX (1) MXPA06012225A (pt)
PL (1) PL1740164T3 (pt)
PT (1) PT1740164E (pt)
SI (1) SI1740164T1 (pt)
WO (1) WO2005105069A1 (pt)
ZA (1) ZA200607988B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1722780A4 (en) * 2003-11-26 2008-12-17 Univ Duke METHOD FOR PREVENTING OR TREATING GLAUCOMA
WO2007070866A2 (en) * 2005-12-16 2007-06-21 Alcon, Inc. Control of intraocular pressure using alk5 modulation agents
ATE552825T1 (de) 2006-04-26 2012-04-15 Rosemont Pharmaceuticals Ltd Flüssige orale zusammensetzungen
US20090202524A1 (en) * 2007-10-31 2009-08-13 Alcon Research, Ltd. Pai-1 expression and activity inhibitors for the treatment of ocular disorders
ES2330184B1 (es) * 2008-06-03 2010-07-05 Neuron Biopharma, S.A. Uso de estatinas como anticonvulsivantes, antiepilepticos y neuroprotectores.
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
CN102093984B (zh) * 2010-11-23 2012-07-04 清华大学 一种杂合酶P450sca2-BMR及其编码基因与应用
EP2809319B1 (en) * 2012-02-02 2018-04-18 The University of Sydney Improvements in tear film stability
GB201611782D0 (en) * 2016-07-06 2016-08-17 Optibiotix Ltd Composition
US10696638B2 (en) 2017-12-26 2020-06-30 Industrial Technology Research Institute Compounds for inhibiting AGC kinase and pharmaceutical compositions comprising the same

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2534580A1 (fr) * 1982-10-13 1984-04-20 Synthelabo Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent
FR2585708B1 (fr) * 1985-07-31 1989-07-07 Sanofi Sa Derives aminoalcools peptidiques inhibiteurs de la resine et des proteases acides, leur procede de preparation et leur application en therapeutique
US5151444B1 (en) * 1987-09-18 1999-07-06 R Tech Ueno Ltd Ocular hypotensive agents
JP2721414B2 (ja) * 1988-09-06 1998-03-04 フアーマシア・アンド・アツプジヨン・アー・ベー 縁内障または眼圧亢進の治療のためのプロスタグランジン誘導体
US5296504A (en) * 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
FR2647675B1 (fr) * 1989-06-05 1994-05-20 Sanofi Utilisation d'un derive de la statine dans le traitement des affections oculaires
JPH04243835A (ja) * 1990-08-29 1992-08-31 Pfizer Inc 高眼圧症又は緑内障治療用薬剤組成物及び治療方法
US5352708A (en) * 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US5599535A (en) * 1995-06-07 1997-02-04 Regents Of The University Of California Methods for the cyto-protection of the trabecular meshwork
US6586425B2 (en) * 1996-02-21 2003-07-01 Wisconsin Alumni Research Foundation Cytoskeletal active agents for glaucoma therapy
US6569461B1 (en) * 1999-03-08 2003-05-27 Merck & Co., Inc. Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
US20020156122A1 (en) * 2000-09-19 2002-10-24 Novlmmune S.A. Statins (HMG-CoA reductase inhibitors) as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent
US20030065020A1 (en) * 2001-07-13 2003-04-03 Catharine Gale Treatment of macular degeneration
US20030195167A1 (en) * 2002-04-15 2003-10-16 Kowa Co., Ltd. PTX3-gene expression inhibitor
JP2004149480A (ja) * 2002-10-31 2004-05-27 Saisentan Igaku Kenkyusho:Kk 経口又は経皮投与用の眼科疾患治療剤
EP1626713A2 (en) * 2003-05-16 2006-02-22 Ambit Biosciences Corporation Heterocyclic compounds and uses thereof
US20040248972A1 (en) * 2003-05-16 2004-12-09 Ambit Biosciences Corporation Compounds and uses thereof
EP1631279A4 (en) * 2003-05-30 2007-03-14 Combinatorx Inc COMBINED THERAPY FOR THE TREATMENT OF NEOPLASMS
EP1722780A4 (en) * 2003-11-26 2008-12-17 Univ Duke METHOD FOR PREVENTING OR TREATING GLAUCOMA
US20090202524A1 (en) * 2007-10-31 2009-08-13 Alcon Research, Ltd. Pai-1 expression and activity inhibitors for the treatment of ocular disorders

Also Published As

Publication number Publication date
CN1946384A (zh) 2007-04-11
WO2005105069A1 (en) 2005-11-10
JP2007534699A (ja) 2007-11-29
AU2005237543B2 (en) 2011-02-10
DK1740164T3 (da) 2008-11-10
SI1740164T1 (sl) 2009-02-28
HK1102913A1 (en) 2007-12-07
KR20110091600A (ko) 2011-08-11
KR20070007932A (ko) 2007-01-16
ES2311986T3 (es) 2009-02-16
PT1740164E (pt) 2008-10-21
EP1740164A1 (en) 2007-01-10
CA2560167A1 (en) 2005-11-10
EP1740164B1 (en) 2008-08-13
DE602005008935D1 (de) 2008-09-25
MXPA06012225A (es) 2007-01-31
CY1108490T1 (el) 2014-04-09
US20110098314A1 (en) 2011-04-28
AU2005237543A1 (en) 2005-11-10
ATE404189T1 (de) 2008-08-15
PL1740164T3 (pl) 2009-01-30
ZA200607988B (en) 2007-12-27
CN1946384B (zh) 2011-04-20
KR101071192B1 (ko) 2011-10-10
US20050239871A1 (en) 2005-10-27

Similar Documents

Publication Publication Date Title
CY1108490T1 (el) Στατινες για την αντιμετωπιση της οφθαλμικης υπερτασης και του γλαυκωματος
WO2006066103A3 (en) Ophthalmic implant for treatment of glaucoma
EA200701134A1 (ru) Средство для профилактики или лечения глаукомы
WO2007076360A8 (en) (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)- pyrazines for treating rho kinase-mediated diseases and conditions
WO2003092584A3 (en) Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
WO2006071548A3 (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases
WO2005002520A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2006044425A3 (en) Ophthalmic compositions for treating ocular hypertension
HK1082668A1 (en) Remedies for glomerular diseases
BR0210241A (pt) Piranoindazóis e seu uso no tratamento de glaucoma
ATE359794T1 (de) 3, 7 thiaprostansäurederivate als mittel zur verminderung des augeninnendruckes
TW200501949A (en) Ophthalmic compositions for treating ocular hypertension
WO2005020917A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2004043354A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2007045930A3 (en) Modulation of trpv expression levels
WO2006020003A3 (en) Ophthalmic compositions for treating ocular hypertension
BR0314419A (pt) Compostos de 5-croman-5-il-etilamina substituìdos, seu uso e composição farmacêutica incluindo-o
ATE409491T1 (de) Orhthalmologische zusammenstellungen zur behandlung von ocularer hypertension
MXPA04006029A (es) Derivados novedosos de benzofuranimidazolina y benzodifuranimidazolina y su uso para el tratamiento de glaucoma.
BR0316775A (pt) Novos análogos de benzopirano e seu uso para o tratamento de glaucoma
AU2001267864A1 (en) Remedial agent for optic nerve disease and the like
MXPA04001255A (es) Uso de compuesto para el tratamiento de condiciones que resultan de lesion al nervio corneo despues de lasik y otras cirugias oculares o trauma.
BR0215752A (pt) Piranoindazóis e seu uso no tratamento de glaucoma
WO2022104102A3 (en) Materials and methods for treating corneal dysfunction
WO2002060339A3 (en) Ophthalmic compositions for treating ocular hypertension

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.